ZHIFEI-BIOL(SZ:300122) Xin Lang Cai Jing·2025-09-18 02:03Group 1 - The core viewpoint of the news is that Zhifei Biological has seen a significant increase in its stock price, rising by 5.23% to 22.92 CNY per share, with a trading volume of 396 million CNY and a market capitalization of 54.866 billion CNY [1] - Zhifei Biological, established on July 20, 1995, and listed on September 28, 2010, is primarily engaged in the research, production, and sales of vaccines and biological products [1] - The company's revenue composition shows that 88.84% comes from agency products, 10.15% from self-developed products, and 1.00% from other sources [1] Group 2 - From the perspective of major fund holdings, one fund under the Fortune Fund has a significant position in Zhifei Biological, with the Fortune National Vaccine and Biotechnology ETF (159645) increasing its holdings by 11,400 shares in the second quarter, totaling 77,600 shares, which accounts for 7.88% of the fund's net value [2] - The Fortune National Vaccine and Biotechnology ETF (159645) was established on September 16, 2022, with a latest scale of 19.2941 million CNY, and has achieved a year-to-date return of 16.76% [2] - The fund manager, Cai Kaer, has been in position for 8 years and 258 days, overseeing total assets of 58.819 billion CNY, with the best fund return during his tenure being 64.74% [2]